Biophytis (EPA:ALBPS) | WebDisclosure

Basculer en Français

8301	Companies
115073	Keywords
55420	Articles
62512	Press releases

Home
Companies
Biophytis

BRIEF

published on 07/22/2024 at 07:05, 3 months 30 days ago

Biophytis Signs Contracts with Local Agents in Asia

Biotechnology Pharmaceutical Partnerships Age-related Diseases Asia Market
BRIEF

published on 07/22/2024 at 07:05, 3 months 30 days ago

Biophytis déploie sa stratégie de partenariats en Asie

Développement Partenariats Asie Santé Biophonobiophytis
REGULATED PRESS RELEASE

published on 07/22/2024 at 07:00, 3 months 30 days ago

Biophytis deploys its partnership strategy and signs two contracts with local agents in Asia
Biophytis implements partnership strategy in Asia with new contracts to advance drug candidate BIO101 in Japan, South Korea, China, and Southeast Asia

Biophytis Asia Contracts Partnership Strategy Drug Candidate BIO101
REGULATED PRESS RELEASE

published on 07/22/2024 at 07:00, 3 months 30 days ago

Biophytis déploie sa stratégie de partenariats et signe deux contrats avec des agents locaux en Asie
Biophytis annonce le déploiement de sa stratégie de partenariats en Asie en signant deux contrats avec des agents locaux pour BIO101 afin d'accélérer son développement sur les marchés clés comme le Japon et la Chine

Biophytis Partenariats Asie Contrats BIO101
BRIEF

published on 07/11/2024 at 08:18, 4 months 10 days ago

Biophytis Obtains IND Approval from FDA for Phase 2 Obesity Study

Biophytis FDA Approval Phase 2 Clinical Trial BIO101 Obesity Study
BRIEF

published on 07/11/2024 at 08:18, 4 months 10 days ago

Biophytis obtient l'approbation IND de la FDA pour une étude de phase 2 sur l'obésité

Biophytis Approbation De La FDA Essai Clinique De Phase 2 BIO101 Étude Sur L'obésité
PRESS RELEASE

published on 07/11/2024 at 08:13, 4 months 10 days ago

Biophytis obtient l’autorisation IND de la FDA pour démarrer son étude OBA de phase 2 dans l’obésité
Biophytis obtient l'autorisation IND de la FDA pour démarrer son étude OBA de phase 2 dans l'obésité. L'étude vise à mesurer l'amélioration de la force musculaire et la composition corporelle

FDA Biophytis Obésité Autorisation IND Étude OBA
PRESS RELEASE

published on 07/11/2024 at 08:13, 4 months 10 days ago

Biophytis obtains IND approval from the FDA to start its phase 2 OBA study in obesity
Biophytis receives FDA IND approval for phase 2 OBA study in obesity with BIO101 (20-hydroxyecdysone), focusing on muscle strength improvement. Study led by renowned expert Marc-André Cornier

FDA Biophytis Obesity IND Approval OBA Study
BRIEF

published on 07/11/2024 at 07:06, 4 months 10 days ago

Biophytis Receives FDA IND Approval for Phase 2 Obesity Study

Biophytis FDA Approval Phase 2 Study BIO101 Obesity
BRIEF

published on 07/11/2024 at 07:06, 4 months 10 days ago

Biophytis obtient l’autorisation IND de la FDA pour une étude de phase 2 dans l’obésité

FDA Biophytis Étude Clinique BIO101 Obésité

Accesswire

Published on 11/21/2024 at 17:35, 45 minutes ago

1upHealth Ranked Number 43 Fastest-Growing Company in North America on the 2024 Deloitte Technology Fast 500(TM)
Published on 11/21/2024 at 17:30, 50 minutes ago

SimpliGov and Proof Partner to Offer Online Notarization
Published on 11/21/2024 at 16:30, 1 hour 50 minutes ago

The Rise of DINKs: Dual-Income Couples Without Kids Redefine Financial Priorities in America
Published on 11/21/2024 at 16:01, 2 hours 19 minutes ago

Career Certified Extends Its Investment in the Fast-Growing Architecture, Engineering, and Construction (AEC) Professionals Market with Acquisition of My Contractors License
Published on 11/21/2024 at 16:00, 2 hours 20 minutes ago

Financial Independence Group Announces Exclusive Partnership With Power of Zero and Tax-Free Retirement Expert David McKnight

View all ACCESSWIRE

EQS Group

Published on 11/21/2024 at 17:58, 21 minutes ago

Funding Circle Plc: POS-Transaction in Own Shares
Published on 11/21/2024 at 17:51, 28 minutes ago

LIGHTON announces highly successful IPO on Euronext Growth Paris.
Published on 11/21/2024 at 17:51, 28 minutes ago

LIGHTON annonce le vif succès de son introduction en Bourse sur Euronext Growth Paris.
Published on 11/21/2024 at 17:51, 28 minutes ago

2CRSi SA: 2CRSi supplies Exaion, a subsidiary of the EDF Group, with high-performance immersion servers in North America.
Published on 11/21/2024 at 17:51, 28 minutes ago

2CRSi SA: 2CRSi fournit à Exaion, filiale du groupe EDF, des serveurs à hautes performances en immersion en Amérique du Nord

Les Echos

Published on 11/21/2024 at 06:58, 11 hours 22 minutes ago

Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/21/2024 at 06:58, 11 hours 22 minutes ago

Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/21/2024 at 06:58, 11 hours 22 minutes ago

Netto-actiefwaarde per aandeel stijgt in zes maanden met 9,4% tot EUR 55,6 dankzij aanhoudend sterke groeiprestaties van portefeuille
Published on 11/20/2024 at 20:07, 22 hours 12 minutes ago

Entech : Nouveaux objectifs stratégiques à moyen-terme et Chiffre d’Affaires du 1er semestre 2024
Published on 11/20/2024 at 19:20, 23 hours ago

Peugeot Invest Board of Directors to evolve following the May 2025 Annual General Meeting

View all LES ECHOS COMFI WIRE